Opiant Pharmaceuticals (OPNT) 10-Q2020 Q1 Quarterly report

Filed: 12 May 20, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abbreviated, adequate, agent, Aid, alongside, billion, British, build, Center, chain, China, claim, claiming, conversation, cooperative, counteract, CRADA, currency, declared, delayed, Department, directly, dismissing, distributor, Divestiture, downturn, driven, eased, economic, economy, entry, essential, experience, exposure, extensive, fifty, fire, flow, foreign, fully, functional, furlough, growing, healthcare, healthy, heighten, high, hold, home, ideal, identified, impossible, indirect, infrastructure, irritation, Justice, large, leadership, legislation, lifting, LLP, local, mandatory, manner, maximize, medical, monitor, negative, negatively, ordinary, outbreak, pandemic, pause, PD, percent, pharmacodynamic, pharmacokinetic, pharmacy, piad, platform, potency, predicated, prescription, proclaimed, regional, requested, resolve, resolved, responder, retail, rule, scale, sensitization, settlement, shareholder, significantly, situation, slightly, society, spread, strategy, stronger, substantial, support, synthetic, telephone, therefrom, threat, translated, translation, Translational, world, Wuhan

Removed: absence, account, accounted, acquiring, agree, amounted, announced, AOCI, attributed, Baker, bear, beginning, binding, BioSolution, Boulevard, branded, broaden, CA, classification, classified, collaborative, commenced, commencing, commercialized, competing, competition, competitor, covering, data, decide, disaggregated, disclose, dispensing, diversity, excluding, execution, feedback, filer, filled, finance, formulation, individual, Interaction, introduce, introduction, invention, judicial, Lakewood, launch, leasing, lessee, liable, located, London, mandate, marketplace, monthly, multiple, mutual, naltrexone, negotiate, Notwithstanding, package, packaging, participant, partner, pattern, percentage, permitted, physician, positive, practical, practice, prescribing, proposal, protected, protection, pursue, quality, raw, Reclassification, reclassify, recruiting, reform, relation, Renaissance, rental, retained, retrospective, software, space, stability, Standish, statement, stranded, Street, sublease, Suite, Supplemental, transaction, uncured, unit, USA, utilize, validity, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated OPNT transcripts

OPNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Opiant Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dr. Roger Crystal, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2020



By:	/s/ Dr. Roger Crystal
Dr. Roger Crystal
Chief Executive Officer
(Principal Executive Officer)